Drugmaker revenues beat analyst estimates
However, the Nasdaq-quoted company — which moved its headquarters to Dublin following its near €1bn takeover of Elan’s Athlone-based drug delivery business in 2011 — also reported a net loss of $40m, up from a loss of $7.8m for the same period last year.
Chief financial officer James Frates said the quarterly results demonstrate the company’s strong financial and operational position, “with a robust portfolio of commercial products generating significant revenue, funding the development of our pipeline of CNS [central nervous system] candidates”.
